Background: NXL104 potentiates ceftazidime and ceftaroline against Enterobacteriaceae with extended-spectrum, AmpC, KPC and OXA b-lactamases. We examined whether similar potentiation was obtained against non-fermenters, which are less permeable than Enterobacteriaceae and have more potent efflux.
Introduction
NXL104 is a novel-structure inhibitor of class A and C b-lactamases that is able to restore susceptibility to ceftazidime and ceftaroline for Enterobacteriaceae with extended-spectrum, AmpC, KPC and OXA-48 carbapenemases, but not for those with metalloenzymes. 1, 2 Its potential to reverse b-lactamase-mediated resistance in Pseudomonas aeruginosa has not been investigated, and this organism presents a dual challenge to b-lactamase inhibitors as it is inherently less permeable than Enterobacteriaceae and is better able to efflux toxic molecules via MexAB-OprM and other systems. 3 Moreover, oxyimino-cephalosporin resistance is determined by a wider diversity of mechanisms than are prevalent in Enterobacteriaceae, including up-regulated efflux, derepressed chromosomal AmpC b-lactamase, unusual class A extendedspectrum b-lactamases (ESBLs) such as PER and VEB, and OXA (class D) ESBLs, as well as metallo-carbapenemases and KPC carbapenemases. 3, 4 Isolates from patients with cystic fibrosis (CF) are particularly problematic, as they are often highly resistant owing to possession of multiple mutational mechanisms. 5, 6 The present study investigated the extent to which NXL104 overcomes ceftazidime resistance in P. aeruginosa. Limited studies also were undertaken on Burkholderia cepacia complex isolates from patients with CF and on Acinetobacter baumannii with cephalosporin and carbapenem resistance determined by OXA carbapenemases.
Materials and methods
P. aeruginosa AmpC inducibility mutants and PU21 transconjugants with different b-lactamases were described previously, as were the collections of strains with various levels of expression of efflux-dependent resistance to cephalosporin, penicillin and non-b-lactam antibiotics. AmpC-derepressed P. aeruginosa isolates were recent clinical submissions to the reference laboratory with positive ceftazidime/boronic acid synergy results as tested using 30 mg ceftazidime discs together with 30 mg boronic acid discs (Neo-Sensitabs; BioConnections, Leeds, UK); those with PER and VEB b-lactamases were collected in Turkey 8 or were recent UK reference submissions. CF isolates of P. aeruginosa (n¼25) and the B. cepacia complex (n¼54) were recent UK reference submissions; gene expression in the P. aeruginosa series has been investigated. 6 The A. baumannii isolates with OXA carbapenemases likewise were recent reference submissions, characterized as described previously.
9 -12 P. aeruginosa isolates were identified by pyocyanin and oxidase production. B. cepacia complex isolates were identified to species level by a combination of recA-based species-specific PCRs and recA sequence cluster analysis.
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NXL104 was obtained from Novexel (Romainville, France), meropenem was obtained from AstraZeneca (Macclesfield, UK), piperacillin and tazobactam were obtained from Wyeth (Taplow, UK) and other antibiotics were obtained from Sigma (Poole, UK). NXL104 is being developed for combination with ceftazidime and ceftaroline. Ceftazidime was chosen as a combination agent in the present studies based on its activity against Pseudomonas. MICs were determined on Mueller-Hinton agar according to CLSI methods; 14 both NXL104 and tazobactam were used at 4 mg/L.
Results

P. aeruginosa laboratory strains with derepressed AmpC or acquired ESBLs
MICs for AmpC inducibility mutants and PU21 transconjugants of P. aeruginosa and clinical isolates with PER and VEB b-lactamases are shown in Table 1 . Several of the isolates with VEB and PER enzymes also produced OXA-10-related ESBLs belonging to molecular class D. NXL104 reduced the MICs of ceftazidime for the fully AmpC-derepressed strains 1405-con and 2297-con from 64-128 to 4-8 mg/L, i.e. to within one doubling dilution of the values for their AmpC-inducible and -basal counterparts. Ceftazidime MICs for AmpC-inducible and -basal organisms were unaffected by NXL104. Potentiation against derepressed organisms was independent of expression of OprD, proving that this 'carbapenem-specific' porin is not involved in the uptake of NXL104.
NXL104 reversed the ceftazidime resistance of a P. aeruginosa PU21 transconjugant with PER-1 enzyme, reducing the MIC from .128 to 4 mg/L (Table 1) . It also reduced the anomalously high MIC for a transconjugant with TEM-2 enzyme from 16 to 1 mg/L, but had little effect on MICs of ceftazidime for transconjugants with ESBL variants of OXA-2 (i.e. OXA-15) and -10 (i.e. OXA-11, -14 and -16, and OXA M101 and OXA M103) enzymes. It reduced the MICs of ceftazidime for clinical P. aeruginosa isolates with PER-1 enzyme alone from .128 to 2 -8 mg/L in five of six cases, though higher MIC values were seen for strains that co-produced OXA-10-related enzymes, including those (OXA-10 itself and OXA-17) with minimal activity against ceftazidime. Ceftazidime MICs for isolates with VEB enzymes were minimally reduced by NXL104.
P. aeruginosa isolates with derepressed AmpC or up-regulated efflux
MICs of unprotected ceftazidime for P. aeruginosa clinical isolates with derepressed AmpC ranged from 8 to .128 mg/L, with 22 of 26 values ≥64 mg/L ( Table 2 ). All except one of these 26 isolates were highly resistant (MICs ≥128 mg/L) to piperacillin with and without tazobactam. Seventeen were susceptible to carbenicillin at ≤256 mg/L and 14 to meropenem at ≤4 mg/L. Carbenicillin and meropenem are poor substrates for AmpC, 15, 16 and the resistance of some isolates probably reflects the simultaneous presence of efflux-and (for meropenem) OprD-related mechanisms. NXL104 potentiated ceftazidime against all AmpCderepressed isolates except one; on average, based on geometric means, ceftazidime MICs were reduced 21-fold, being brought down to 1-8 mg/L. The exceptional isolate probably also had high-level efflux and was only inhibited by ceftazidime+NXL104 at 64 +4 mg/L ( Table 2 ). Since these were clinical isolates we cannot discount the wider presence of additional mechanisms, but, despite this, the general synergy with NXL104 was clear.
Ceftazidime MICs for the isolates varying in efflux-mediated resistance ranged from 0.03 to 16 mg/L, and were correlated with those for carbenicillin, piperacillin, piperacillin+tazobactam and meropenem, which are also excreted by MexA-OprM and other efflux systems ( Table 2 ). MICs of ceftazime+NXL104 were consistently within one doubling dilution of those of unprotected ceftazidime, and the geometric mean reduction in ceftazidime MIC achieved with NXL104 was only 1.1-fold.
MICs of unprotected ceftazidime for isolates of P. aeruginosa from CF ranged from 1 to .128 mg/L, with 13 of 25 values ≥64 mg/L. Most of the organisms with high ceftazidime MICs were cross-resistant to carbenicillin, meropenem and piperacillin, with piperacillin+tazobactam no more active than unprotected piperacillin. Among the eight isolates with ceftazidime MICs at or below the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint of 8 mg/L, only one showed greater than 2-fold potentiation of ceftazidime by NXL104, whereas, among the 17 with MICs .8 mg/L, 11 showed ≥4-fold synergy, with ceftazidime:ceftazidime+NXL104 MIC ratios ranging up to 32, but other isolates, some of them with ceftazidime MICs as high as .256 mg/L, showed little or no synergy (Table 2) . Geometric mean fold reductions in MIC are meaningless in the face of such scatter, and were not calculated.
Activity versus B. cepacia complex isolates from CF
Fifty-four B. cepacia complex isolates were tested, comprising 37 Burkholderia multivorans, 8 B. cepacia, 6 Burkholderia cenocepacia and 3 Burkholderia vietnamiensis. Forty-nine were resistant to ceftazidime, with MICs .8 mg/L, and 32 were highly resistant, with MICs .32 mg/L. Cross-resistance was extensive: all except two were resistant to carbenicillin at 1024 mg/L; 45 of 54 were resistant to piperacillin at 64 mg/L; 41 of 54 were resistant to piperacillin+tazobactam at 64+4 mg/L; and 38 were resistant to meropenem at 8 mg/L. Thirty-six of the 54 isolates were susceptible to ceftazidime+NXL104 8+4 mg/L, representing a considerable improvement over unprotected ceftazidime; NXL104 reduced the ceftazidime MIC by at least 4-fold in 35 cases and by ≥32-fold in 10. There was no consistent relationship between the magnitude of the ceftazidime MIC, the species, and the occurrence or extent of synergy with NXL104. Thus, among 18 isolates with ceftazidime MICs ≥128 mg/L, 16 of them identified as B. multivorans, 6 showed no potentiation by NXL104, whereas 8 showed ≥32-fold MIC potentiation, with ceftazidime MICs reduced to ≤8 mg/L. up-regulated OXA-51-like. All the isolates except one were unequivocally resistant to meropenem, with MICs ≥16 mg/L, to carbenicillin, with MICs ≥256 mg/L, and to piperacillin, with MICs ≥128 mg/L. Forty-seven of the 51 were resistant to piperacillin+tazobactam at ≥128 mg/L. All except four were resistant to ceftazidime at 8 mg/L, and 44 of the 51 
Discussion
Even 30 years after its launch, ceftazidime remains the most potent antipseudomonal cephalosporin, although CXA-101, which is now in Phase II development, has 4-to 8-fold lower MICs for most isolates and represents a likely improvement. Ceftazidime+NXL104 versus non-fermenters JAC Nevertheless, ceftazidime resistance does arise in P. aeruginosa, in general being more prevalent in the south and east of Europe than in the north or west. 3, 18 Among bloodstream isolates in the UK in 2008, just 3.5% -3.6% were found to be resistant by the European Antimicrobial Resistance Surveillance System (EARSS) and BSAC surveillances, respectively, whereas, based on EARSS data, 37.4% were resistant in the Czech Republic and 43.8% in Greece. 3, 19 Resistance rates are notoriously higher among isolates from patients with CF, reflecting the co-selection of hypermutability with resistance. 5 Ceftazidime resistance in this species is most often mediated by up-regulation of the chromosomal AmpC b-lactamase, or of efflux by MexA-OprM or other pumps, 3 with little comprehensive recent data on the relative prevalence of these two mechanisms. Acquired ceftazidimases are much rarer, except in local outbreaks, but are extremely diverse, including PER, VEB, CTX-M and OXA ESBLs as well as metallo-carbapenemases and KPC carbapenemases. PER-1 ESBL is frequent in Turkey 20 and a clone with SPM-1 metallo-b-lactamase has spread extensively in Brazil.
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NXL104 overcame most AmpC-mediated resistance in P. aeruginosa, reducing ceftazidime MICs to the current EUCAST BSAC susceptibility breakpoint of ≤8 mg/L, even when expression of this enzyme was completely derepressed, as in strains 1405-con and 2297-con (Table 1) . It follows that NXL104 must be able to cross the pseudomonal outer membrane, sufficiently evading efflux and accumulating to an effective concentration in the periplasm. In contrast, and predictably, NXL104 did nothing to reverse efflux-mediated ceftazidime resistance in P. aeruginosa.
Potentiation against P. aeruginosa isolates from patients with CF was extremely variable, probably reflecting variation among strains in the extent to which their resistance reflected derepression of AmpC as against up-regulation of efflux. We have previously measured mRNA levels for AmpC and pump components in these organisms, 6 but attempts to relate the results to the degree of ceftazidime+NXL104 synergy were unsuccessful. This is probably because, even when present, up-regulation of AmpC often was not the sole determinant of ceftazidime resistance. It is also plausible that strongly up-regulated efflux might exclude NXL104, precluding synergy even when AmpC is overexpressed. Perhaps the most that can be said is that ceftazidime+NXL104 should be active against a variable proportion of CF P. aeruginosa isolates, contingent on their particular combinations of resistance determinants. The extent of synergy was generally greater for B. cepacia complex isolates; 36 of 54 (67%) were susceptible to ceftazidime+ NXL104 8 + 4 mg/L versus 5 of 54 (9%) susceptible to ceftazidime alone, with little obvious association between the extent of synergy and the subspecies or the rest of the resistance profile.
In the case of A. baumannii, NXL104 had no useful ability to potentiate ceftazidime against strains with OXA carbapenemases, which also contribute to ceftazidime resistance. 22 It remains to be ascertained whether this failure reflects: (i) the OXA-23, -40, -51 and -58-like carbapenemases being recalcitrant to inhibition by NXL104; (ii) failure of NXL104 to penetrate A. baumannii; or (iii) the widespread presence of other ceftazidimases, although this last possibility seems unlikely because NXL104 would be expected to inhibit most class A or C enzymes. None of the isolates had a metallo-b-lactamase. OXA-23, -40, -51 and -58 enzymes are structurally remote from OXA-48, 23 an enterobacterial carbapenemase that is inhibited by NXL104. 24 It is notable that OXA-48 is related to the OXA-10 group of enzymes, 23 which we found not to be inhibited by NXL104. In summary, these results prove that NXL104 penetrates P. aeruginosa to achieve effective periplasmic levels, overcoming the ceftazidime resistance engendered by AmpC enzymes, even when these are completely derepressed. NXL104 could also overcome PER-1, an important ceftazidimase in Turkey, though it failed to overcome VEB ESBLs, which are also important in P. aeruginosa. It does not inhibit metallo-carbapenemases, which were excluded from this investigation, nor does it reverse resistance associated with OXA ESBLs in P. aeruginosa or with OXA carbapenemases in Acinetobacter spp. It has variable ability to potentiate ceftazidime against P. aeruginosa and B. cepacia complex isolates from patients with CF, this variation presumably reflecting the relative contributions of b-lactamases vis à vis efflux in individual isolates.
